Publications scientifiques Bordet

Publications scientifiques Bordet

Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study.

Van Baelen K, Nguyen HL, Richard F, Zels G, Karsten MM, Nader-Marta G, Vermeulen P, Dirix L, Dordevic AD, de Azambuja E, Larsimont D, Maetens M, Biganzoli E, Wildiers H, Smeets A, Nevelsteen I, Neven P, Floris G, Desmedt C

Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study.

Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study.

Maertens JA, Thompson GR, Spec A, Donovan FM, Hammond SP, Bruns AHW, Rahav G, Shoham S, Johnson R, Rijnders B, Schaenman J, Hoenigl M, Morrissey CO, Mehta SR, Heath CH, Koehler P, Paterson DL, Slavin MA, Fortún J, Nguyen MH, Patterson TF, Uspenskaya O, Van de Veerdonk FL, Verweij PE, Aoun M, Georgala A, Alexander BD, Chayakulkeeree M, Mehra V, Miceli MH, Sikka MK, Solé A, Walsh TJ, Aguado JM, Holland SM, Moussa M, Rautemaa-Richardson R, Bazaz R, Schwartz S, Walsh SR, Plate M, Yehudai-Ofir D, Brüggemann RJ, Cornely OA, Ostrosky-Zeichner L, Vazquez JA, White PL, Cornelissen K, Ross GG, Fitton L, Dane A, Zinzi D, Rex JH, Chen SC

Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study.

Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study.

Maertens JA, Thompson GR, Spec A, Donovan FM, Hammond SP, Bruns AHW, Rahav G, Shoham S, Johnson R, Rijnders B, Schaenman J, Hoenigl M, Morrissey CO, Mehta SR, Heath CH, Koehler P, Paterson DL, Slavin MA, Fortún J, Nguyen MH, Patterson TF, Uspenskaya O, Van de Veerdonk FL, Verweij PE, Aoun M, Georgala A, Alexander BD, Chayakulkeeree M, Mehra V, Miceli MH, Sikka MK, Solé A, Walsh TJ, Aguado JM, Holland SM, Moussa M, Rautemaa-Richardson R, Bazaz R, Schwartz S, Walsh SR, Plate M, Yehudai-Ofir D, Brüggemann RJ, Cornely OA, Ostrosky-Zeichner L, Vazquez JA, White PL, Cornelissen K, Ross GG, Fitton L, Dane A, Zinzi D, Rex JH, Chen SC

Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study.

Comprehensive profiling of the mutational landscape of hidradenoma papilliferum validates key role of alterations in the PI3K/AKT pathway.

Cheema S, van der Weyden L, Wong K, Del Castillo Velasco-Herrera M, Billington J, Vermes I, Anderson E, Allen L, de Saint Aubain N, van der Horst MPJ, Alomari AK, Mogler C, Monteagudo C, Frew D, Billings SD, Arends MJ, Ferreira I, Brenn T, Adams DJ

Comprehensive profiling of the mutational landscape of hidradenoma papilliferum validates key role of alterations in the PI3K/AKT pathway.
Erasme hospital

Hôpital Erasme

Consultez toutes les publications scientifiques d'Erasmus

Publications scientifiques d'Erasmus
Huderf hospital

Hôpital pédiatrique Reine Fabiola

Consultez toutes les publications scientifiques de l'Hôpital pédiatrique Reine Fabiola

Publications scientifiques de l'Hôpital pour enfants Reine Fabiola
Bordet hospital

Institut Jules Bordet

Consultez toutes les publications scientifiques de Jules Bordet

Publications scientifiques de Jules Bordet